Krystal Biotech, Inc.
(NASDAQ : KRYS)

( )
KRYS PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
BMYBristol-Myers Squibb Co.
1.13%64.681.4%$1759.11m
JNJJohnson & Johnson
0.30%141.400.7%$887.79m
PFEPfizer Inc.
0.29%38.650.9%$751.58m
MRKMerck & Co., Inc.
-0.01%89.550.7%$683.61m
ABBVAbbVie, Inc.
2.34%88.732.3%$613.50m
LLYEli Lilly & Co.
0.76%121.701.1%$364.29m
NVSNovartis AG
-0.17%92.900.2%$148.18m
AZNAstraZeneca Plc
1.31%48.561.2%$139.40m
GSKGlaxoSmithKline Plc
0.81%46.310.2%$136.56m
KRTXKaruna Therapeutics, Inc.
2.18%75.110.0%$119.57m
RETAReata Pharmaceuticals, Inc.
0.76%201.053.5%$112.61m
SNYSanofi
0.67%49.840.2%$109.09m
NVONovo Nordisk A/S
1.36%57.280.1%$92.04m
ALLKAllakos, Inc.
3.88%125.970.0%$76.16m
FTSVForty Seven, Inc.
0.67%39.000.0%$53.57m

Company Profile

Krystal Biotech, Inc. is a gene therapy company, which engages in developing and commercializing treatment for patients suffering from dermatological diseases. It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which company believe there are no known effective treatments. The company was founded by Suma M. Krishnan in December 2017 and is headquartered in Pittsburgh, PA.